Curcumin

Property	Information
Drug Name	Curcumin
FDA Approval	No (Used as a dietary supplement; not FDA-approved for cancer treatment)
Used for	Investigational use in cancer treatment and prevention; also used for symptom management like dermatitis from radiotherapy
Clinical Trial Phase	Preclinical studies and early clinical trials
Clinical Trial Explanation	Not specified
Common Side Effects	Generally well-tolerated; bioavailability issues are noted, but can be improved with piperine
OS without	Not specified
OS with	Not applicable; studies focus on cellular and symptom management rather than direct survival outcomes
PFS without	Not specified
PFS with	Not applicable; research has not extensively measured progression-free survival in cancer patients
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	1
Toxicity Explanation	Not specified

Notes: Curcumin, derived from turmeric, exhibits multiple anti-cancer properties in laboratory studies, including inhibition of tyrosine kinase signaling, angiogenesis, and promotion of apoptosis via NF-kB inhibition. Its bioavailability is limited but can be enhanced with piperine. Clinical evidence of its effectiveness includes reducing dermatitis in breast cancer radiotherapy and decreasing polyp size and number in colon conditions. While promising in laboratory settings for its anti-cancer potential, further research is required to fully understand its clinical efficacy and optimal use in cancer treatment.

From Ben Williams Book: Not specified

Loading comments...